drugset / Trial / NCT03129074
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the efficacy of varlitinib in combination with capecitabine as measured by objective response rate (ORR) assessed by independent central review (ICR), based on RECIST v1.1 criteria.
Timeline
- Start
- 2018-05
- Primary completion
- 2020-03
- Completion
- 2020-09
Outcome
Outcome not reported
Stopped (Business): “sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Varlitinib | Small molecule | 300 mg | Oral |